Allergen Research Corporation (ARC), a San Mateo, CA-based developer of desensitization treatment protocols and products for food allergies, completed a $17m Series A financing.
The round was led by Longitude Capital, with support from Food Allergy Research & Education (FARE), a nonprofit focused on food allergies. In conjunction with the funding, Patrick Enright, managing director of Longitude Capital, joined ARC’s board of directors.
Founded in 2011 and led by CEO Bryan Walser, MD, Allergen Research Corporation is developing treatments to protect children with food allergies from the consequences of accidental exposure. Its lead product is a pharmaceutical-grade formulated peanut protein with gradual, controlled up-dosing and ongoing maintenance dosing.
The company intends to use the funds to support its upcoming Phase 2b clinical trial to evaluate peanut allergy oral immunotherapy (OIT) with characterized peanut allergen (CPNA), as well as related development projects.
ARC expects to begin its Phase 2b trial in the fourth quarter of 2013.